Actinium Pharmaceuticals names Steffen Heeger chief medical officer

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00
  • Actinium Pharmaceuticals appointed Steffen Heeger as chief medical officer on June 1, 2026, as it advances Actimab-A, ATNM-400, Iomab-ACT into 2H 2026 readouts.
  • Heeger was most recently CMO at Full-Life Technologies, overseeing global development and regulatory work for a radiotherapy pipeline, including an anti-PSMA program.
  • He previously served as CMO at NBE Therapeutics, acquired by Boehringer Ingelheim for USD 1.4 billion.
  • Earlier roles include VP and head of clinical development at MorphoSys, plus nearly a decade leading global clinical development for Erbitux at Merck KGaA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY72092) on June 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.